Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 13/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | KLK7 | P49862 | 2/20 | 0.36 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.36 |
| ▸ | WNT3A | P56704 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765831 | 0.93 | CASP1 (0.40) | ELANECASP1WNT3ACYP3A4 | |
| SCHEMBL30765546 | 0.92 | CASP1 (0.40) | ELANECASP1BCHEWNT3ACYP3A4 | |
| SCHEMBL30765555 | 0.88 | CASP1 (0.42) | ELANECASP1WNT3ACYP3A4 | |
| SCHEMBL30765738 | 0.85 | CASP1 (0.42) | ELANECASP1BCHEWNT3ACYP3A4 | |
| SCHEMBL30765956 | 0.84 | CASP1 (0.41) | ELANECASP1WNT3A | |
| SCHEMBL30765726 | 0.83 | BCHE (0.44) | ELANEBCHE | |
| SCHEMBL30765664 | 0.80 | BCHE (0.44) | ELANEBCHEKLK7KLK5 | |
| SCHEMBL30765765 | 0.79 | CASP1 (0.43) | ELANECASP1WNT3A | |
| SCHEMBL30766052 | 0.78 | KLK7 (0.42) | ELANEBCHEKLK7KLK5 | |
| SCHEMBL30765638 | 0.78 | GAA (0.41) | ELANEBCHEKLK7KLK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |